Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kintor Pharmaceutical Ltd ( (HK:9939) ) has shared an update.
Kintor Pharmaceutical Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025, and to approve their release to the public. The announcement signals the forthcoming disclosure of Kintor’s full-year financial and operational performance, a key event for investors and other stakeholders assessing the company’s progress and outlook.
The most recent analyst rating on (HK:9939) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a Hong Kong–listed biopharmaceutical company incorporated in the Cayman Islands, focused on the research, development and commercialization of pharmaceutical products. The company operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard governance structure for a listed life sciences firm.
Average Trading Volume: 1,812,596
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.39B
See more data about 9939 stock on TipRanks’ Stock Analysis page.